4.6 Article

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease

期刊

ALZHEIMERS RESEARCH & THERAPY
卷 11, 期 1, 页码 -

出版社

BMC
DOI: 10.1186/s13195-019-0533-9

关键词

Alzheimer's disease; Biomarker; CSF; Mass spectrometry; Parkinson's disease

资金

  1. Eivind and Elsa K: Son Sylvans Foundation
  2. Martha and Gustaf Agrens Foundation
  3. Swedish Brain Foundation
  4. Torsten Soderberg Foundation
  5. Swedish Alzheimer foundation
  6. Foundation for Gamla Tjanarinnor
  7. Swedish Research Council [20112-2288, 2013-2546]
  8. Parkinson foundation of Sweden
  9. Demensfonden
  10. Ahlen Foundation
  11. Gun and Bertil Stohnes Foundation
  12. Wilhelm and Martina Lundgrens Science Foundation
  13. European Research Council [681712]
  14. Frimurarestiftelsen
  15. Knut and Alice Wallenberg Foundation [KAW 2013.0180]
  16. MRC [MR/K01417X/1, MR/J004758/1, G1001253, G0901254, MR/N026004/1, UKDRI-1009, G0701075] Funding Source: UKRI

向作者/读者索取更多资源

Background Increasing evidence implicates dysfunctional proteostasis and the involvement of the autophagic and endo-lysosomal system and the ubiquitin-proteasome system in neurodegenerative diseases. In Alzheimer's disease (AD), there is an accumulation of autophagic vacuoles within the neurons. In Parkinson's disease (PD), susceptibility has been linked to genes encoding proteins involved in autophagy and lysosomal function, as well as mutations causing lysosomal disorders. Furthermore, both diseases are characterized by the accumulation of protein aggregates. Methods Proteins associated with endocytosis, lysosomal function, and the ubiquitin-proteasome system were identified in the cerebrospinal fluid (CSF) and targeted by combining solid-phase extraction and parallel reaction monitoring mass spectrometry. In total, 50 peptides from 18 proteins were quantified in three cross-sectional cohorts including AD (N = 61), PD (N = 21), prodromal AD (N = 10), stable mild cognitive impairment (N = 15), and controls (N = 68). Results A pilot study, including subjects selected based on their AD CSF core biomarker concentrations, showed increased concentrations of several targeted proteins in subjects with core biomarker levels indicating AD pathology compared to controls. Next, in a clinically characterized cohort, lower concentrations in CSF of proteins in PD were found compared to subjects with prodromal AD. Further investigation in an additional clinical study again revealed lower concentrations in CSF of proteins in PD compared to controls and AD. Conclusion In summary, significantly different peptide CSF concentrations were identified from proteins AP2B1, C9, CTSB, CTSF, GM2A, LAMP1, LAMP2, TCN2, and ubiquitin. Proteins found to have altered concentrations in more than one study were AP2B1, CTSB, CTSF, GM2A, LAMP2, and ubiquitin. Interestingly, given the genetic implication of lysosomal function in PD, we did identify the CSF concentrations of CTSB, CTSF, GM2A, and LAMP2 to be altered. However, we also found differences in proteins associated with endocytosis (AP2B1) and the ubiquitin-proteasome system (ubiquitin). No difference in any peptide CSF concentration was found in clinically characterized subjects with AD compared to controls. In conclusion, CSF analyses of subjects with PD suggest a general lysosomal dysfunction, which resonates well with recent genetic findings, while such changes are minor or absent in AD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据